AbC-19™ IgG LFD successfully used semi-quantitively to monitor vaccine responses to variant proteins

York, U.K. 27 July 2021:  The UK-RTC, a consortium of UK diagnostic companies including Abingdon Health, CIGA Healthcare, BBI Solutions and Omega Diagnostics welcomes the publication of an article illustrating the use of the AbC-19TM IgG spike antibody lateral flow device (AbC-19TM LFD) in semi-quantitative format and antibody responses against covid variants of concern.

The article demonstrates that AbC-19TM is able to monitor antibody response following vaccination or natural infection. The paper shows differences in strength of antibody response with the Pfizer and AstraZeneca (“AZ”) vaccines and the induced antibody responses to the original Wuhan variant, on which the vaccines are based. It also shows that these antibodies cross-react to the ‘spike protein’ of different variants of concern. This study was conducted using the AbC-19TM LFD and prototypes based on different covid variants.  The  results demonstrated a stronger antibody response in those vaccinated by Pfizer, compared to AZ, whilst noting the cohort vaccinated with AZ were older, which the authors noted may have an effect on antibody response.

The authors used a semi-quantitative score card to record the strength of the test-line response on the LFD.   They illustrated pictorially and in graphical format a proportional response of line intensity to the concentrations of neutralising antibodies in a serial dilution  of the WHO standard 20/136 from 1000 IU/mL down to 7.8 IU/mL which covers the range that previous research has shown to be indicative of immunity. (The WHO standard 20/136 is for the calibration and harmonization of serological assays detecting anti-SARS-CoV-2 neutralising antibodies).

The article by researchers at the University of Birmingham is published as: Ebanks, D et al, “Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays” Journal of Infection on 26th July 2021. To view the full paper, please click here.

Professor Chris Molloy, Independent chairman of the UK Rapid Test Consortium said: “Mass rapid testing is proving to be a vital tool that helps vaccinated nations release themselves from lockdown. This new data shows that antibody tests are part of that toolset, providing assurance both to citizens and public health bodies”.

 

About the UK-RTC

The UK Rapid Test Consortium (UK-RTC) was founded in response to a UK Government call for businesses to work together on a rapid antibody test to be rolled out nationally. Led by Abingdon Health, it’s members also include, BBI Solutions, CIGA Healthcare and Omega Diagnostics. The AbC-19TM is approved in Europe and the UK for professional use.

Click here to contact us about AbC-19TM.

About the AbC-19™ Rapid Test 

The AbC-19™ Rapid Test is a single use test for the detection of neutralising IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus in human capillary whole blood.